Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLAW) Expands By 54.2%

Estrella Immunopharma, Inc. (NASDAQ:ESLAW) was the recipient of a significant increase in short interest during the month of February. As of February 13th, there was short interest totaling 26,312 shares, an increase of 54.2% from the January 29th total of 17,060 shares. Based on an average trading volume of 5,539 shares, the days-to-cover ratio is presently 4.8 days. Based on an average trading volume of 5,539 shares, the days-to-cover ratio is presently 4.8 days.

Estrella Immunopharma Stock Down 5.0%

Shares of ESLAW stock opened at $0.08 on Friday. Estrella Immunopharma has a 52-week low of $0.03 and a 52-week high of $0.24. The firm’s 50-day moving average is $0.06 and its 200-day moving average is $0.07.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.